These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
MDUK and Healx announce new partnership to identify FSHD treatmentsRead more
Fulcrum Therapeutics has announced that the FDA has granted Orphan Drug designation to losmapimod for the treatment of patients with FSHD in the USA.
Facio Therapies has announced the completion of a ‘real-world data’ study monitoring the progression of FSHD and its impact on daily life.
Acceleron Pharma has announced topline results from its phase 2 trial testing ACE-083 in adults with facioscapulohumeral muscular dystrophy (FSHD).
Muscular Dystrophy UK is investing £1.2 million into 9 new research projects this year, bringing our total research portfolio to over £10m.
Scientists from Fred Hutchinson Cancer Research Center (USA) have identified a new role for DUX4, the gene that is mutated in FSHD
The FSH Society International Research Congress was held in France, on 19-20 June 2019
Fulcrum Therapeutics has obtained rights to losmapimod from GSK. Fulcrum is interested in the drug because it has found that it can switch off DUX4 in FSHD cells.
Facio Therapies announced today that it has completed a comprehensive search for new FSHD drug candidates.
A recent study has demonstrated the value of a new mouse model of facioscapulohumeral muscular dystrophy (FSHD).
Facio Therapies has shown that one of its lead compounds can reduce the levels of DUX4 in a mouse model.